[go: up one dir, main page]

GB9726388D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB9726388D0
GB9726388D0 GBGB9726388.3A GB9726388A GB9726388D0 GB 9726388 D0 GB9726388 D0 GB 9726388D0 GB 9726388 A GB9726388 A GB 9726388A GB 9726388 D0 GB9726388 D0 GB 9726388D0
Authority
GB
United Kingdom
Prior art keywords
chemical compounds
aryl
alkyl
hydrogen
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9726388.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand UK Research Ltd
Original Assignee
Cerebrus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerebrus Ltd filed Critical Cerebrus Ltd
Priority to GBGB9726388.3A priority Critical patent/GB9726388D0/en
Publication of GB9726388D0 publication Critical patent/GB9726388D0/en
Priority to US09/581,340 priority patent/US6500866B1/en
Priority to AU14982/99A priority patent/AU1498299A/en
Priority to AT98959052T priority patent/ATE225768T1/en
Priority to PCT/GB1998/003715 priority patent/WO1999031051A1/en
Priority to EP98959052A priority patent/EP1037874B1/en
Priority to JP2000538980A priority patent/JP2002508350A/en
Priority to ES98959052T priority patent/ES2185237T3/en
Priority to DE69808669T priority patent/DE69808669T2/en
Priority to US10/291,413 priority patent/US20030130354A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/16—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Soy Sauces And Products Related Thereto (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Use of a compound of the formula (1), wherein X is an alkylene chain comprising 0, 1, 2, 3 or 4 carbon atoms; R1, R2 and R3 are independently selected from hydrogen, alkyl and aryl; R4, R5 and R6 are independently selected from hydrogen, alkyl, aryl, halogen and alkoxy; and prodrugs thereof and pharmaceutically acceptable salts thereof; in the manufacture of a medicament for use in the treatment of a condition generally associated with abnormalities in glutamatergic transmission.
GBGB9726388.3A 1997-12-12 1997-12-12 Chemical compounds Ceased GB9726388D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB9726388.3A GB9726388D0 (en) 1997-12-12 1997-12-12 Chemical compounds
DE69808669T DE69808669T2 (en) 1997-12-12 1998-12-11 1- (ADAMANTYL) AMIDINE AND THEIR USE IN TREATING CONDITIONS RELATED TO DEVIATIONS IN GLUTAMATERGIC TRANSMISSIONS
PCT/GB1998/003715 WO1999031051A1 (en) 1997-12-12 1998-12-11 1-(adamantyl)amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
AU14982/99A AU1498299A (en) 1997-12-12 1998-12-11 1-(adamantyl)amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
AT98959052T ATE225768T1 (en) 1997-12-12 1998-12-11 1-(ADAMANTYL)AMIDINE AND THEIR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH ALTERATIONS IN GLUTAMATERGIC TRANSMISSIONS
US09/581,340 US6500866B1 (en) 1997-12-12 1998-12-11 1-(adamantyl)amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
EP98959052A EP1037874B1 (en) 1997-12-12 1998-12-11 1-(adamantyl)amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
JP2000538980A JP2002508350A (en) 1997-12-12 1998-12-11 1- (Adamantyl) amidines and their use in treating conditions commonly associated with abnormalities in glutamatergic transmission
ES98959052T ES2185237T3 (en) 1997-12-12 1998-12-11 1- (ASAMANTIL) AMIDINAS AND ITS USE IN THE TREATMENT OF STATES GENERALLY ASSOCIATED WITH ANOMALIES IN THE GLUTAMATERGICAL TRANSMISSION.
US10/291,413 US20030130354A1 (en) 1997-12-12 2002-11-12 1-(Adamantyl) amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9726388.3A GB9726388D0 (en) 1997-12-12 1997-12-12 Chemical compounds

Publications (1)

Publication Number Publication Date
GB9726388D0 true GB9726388D0 (en) 1998-02-11

Family

ID=10823580

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9726388.3A Ceased GB9726388D0 (en) 1997-12-12 1997-12-12 Chemical compounds

Country Status (9)

Country Link
US (2) US6500866B1 (en)
EP (1) EP1037874B1 (en)
JP (1) JP2002508350A (en)
AT (1) ATE225768T1 (en)
AU (1) AU1498299A (en)
DE (1) DE69808669T2 (en)
ES (1) ES2185237T3 (en)
GB (1) GB9726388D0 (en)
WO (1) WO1999031051A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100504A2 (en) 1998-07-02 2001-05-23 Eisai Co., Ltd. Pharmaceutical compositions and their uses for treatment of demyelinating disorders
GB9901691D0 (en) 1999-01-26 1999-03-17 Cerebrus Ltd Chemical compounds
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
ITTO20030668A1 (en) 2003-09-02 2005-03-03 Rotta Res Lab S P A O Ra Rottapharm DERIVATIVES OF ADAMANTAN EQUIPPED WITH NEUROPROTECTIVE, ANTIDEPRESSIVE AND ANTI-ISCHEMIC ACTIVITY AND PROCEDURE FOR THEIR PREPARATION.
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
HUP0401523A3 (en) * 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
RU2434848C2 (en) * 2009-11-30 2011-11-27 Учреждение Российской Академии Наук Институт Нефтехимии И Катализа Ран Method of producing 1-chloro-3-cyanoadamantane

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE151447C (en)
BE795381A (en) * 1972-02-15 1973-08-13 Sandoz Sa DERIVATIVES OF ADAMANIANA
JPS5246949B2 (en) * 1973-10-19 1977-11-29
DD151447A1 (en) * 1980-06-18 1981-10-21 Heinz Paul PROCESS FOR THE PREPARATION OF AMIDINES AND THEIR SALTS
AU671071B2 (en) * 1990-08-30 1996-08-15 State of Oregon, acting by and through The Oregon State Board of Higher Education, acting for and on behalf of The Oregon Health Sciences University, Portland, Oregon, and The University of Oregon, Eugene, Oregon, Johnson Hall, Substituted amidines having high binding to the sigma receptor and the use thereof
US5677349A (en) * 1995-04-27 1997-10-14 Gilad; Gad M. Agmatine for the treatment of neurotrauma and neurodegenerative diseases

Also Published As

Publication number Publication date
WO1999031051A1 (en) 1999-06-24
EP1037874B1 (en) 2002-10-09
JP2002508350A (en) 2002-03-19
ES2185237T3 (en) 2003-04-16
US20030130354A1 (en) 2003-07-10
DE69808669T2 (en) 2003-07-31
AU1498299A (en) 1999-07-05
US6500866B1 (en) 2002-12-31
EP1037874A1 (en) 2000-09-27
ATE225768T1 (en) 2002-10-15
DE69808669D1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
GB0018272D0 (en) Chemical compounds IV
TW369536B (en) Phosphonate nucleotide compounds
EP0842661A3 (en) Atherosclerosis treatment
NZ332762A (en) Isobutylgaba and its derivatives for the treatment of pain
GB9726388D0 (en) Chemical compounds
JO2065B1 (en) Triazine compounds
CA2285535A1 (en) Benzimidazole derivative for treating allergy-related disease
GB9802225D0 (en) Chemical compounds
ES467069A1 (en) Pharmacologically active compounds
GB9901691D0 (en) Chemical compounds
AU2287499A (en) Azetidinecarboxamide derivatives for treating cns disorders
MY103571A (en) Certain 1, 2-benzisoxazole and 1, 2- benzisothiazole derivatives
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders
IL131380A0 (en) The use of a compound for the manufacture of a pharmaceutical preparatin for the treatment or prevention of prostate cancer
EP0785193A4 (en) Arylthiadiazole derivative and antiviral agent containing the same
AU2178099A (en) Azetidinecarboxamide derivatives for treating cns disorders
TW355184B (en) Substituted thiophenylsulfonylureas and -thioureas, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
ES479110A1 (en) Benzamidine derivatives
CA2187402A1 (en) Quinoxaline Derivatives for Treating Tinnitus
TW358809B (en) Phenylamidinothiophene compound and anti-inflammatory agent containing the same
WO1999011621A3 (en) Thiourea for increasing hdl-cholesterol levels, which are useful as anti-atherosclerotic agents
MX9707672A (en) Azole compounds with antimycotic activity for human and veterinary use.
EP0806422A3 (en) Anti-cataract agent
EP0443474A3 (en) 1-phenoxycarbonyl-2-pyrrolidinone derivatives and nootropic agents
AU3479299A (en) N-aryloxyethyl-indoly-alkylamines for the treatment of depression

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)